000179731 001__ 179731
000179731 005__ 20240229145552.0
000179731 0247_ $$2doi$$a10.1186/s12885-022-09582-5
000179731 0247_ $$2pmid$$apmid:35473606
000179731 0247_ $$2altmetric$$aaltmetric:127379184
000179731 037__ $$aDKFZ-2022-00863
000179731 041__ $$aEnglish
000179731 082__ $$a610
000179731 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$udkfz
000179731 245__ $$aCervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment.
000179731 260__ $$aHeidelberg$$bSpringer$$c2022
000179731 3367_ $$2DRIVER$$aarticle
000179731 3367_ $$2DataCite$$aOutput Types/Journal article
000179731 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1651246954_11515
000179731 3367_ $$2BibTeX$$aARTICLE
000179731 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179731 3367_ $$00$$2EndNote$$aJournal Article
000179731 520__ $$aIncidence of cervical cancer has been reduced by organized screening while for vaginal and vulvar cancers no systematic screening has been implemented. All these cancers are associated with human papilloma virus (HPV) infection. We wanted to analyze incidence trends and relative survival in these cancers with specific questions about the possible covariation of incidence, survival changes coinciding with incidence changes and the role of treatment in survival. We used nationwide cancer registry data for Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) to address these questions.We use the NORDCAN database for the analyses: incidence data were available from 1943 in DK, 1953 in FI and NO and 1960 in SE, through 2016. Survival data were available from 1967 through 2016. World standard population was used in age standardization.In each country the incidence of cervical cancer declined subsequent to rolling out of screening activities. The attained plateau incidence was lowest at 4/100,000 in FI and highest at 10/100,000 in DK and NO. The incidence of vaginal and vulvar cancer remained relatively constant at about 2/100,000. Relative 1-year survival in cervical cancer improved in all countries from low 80%s to high 80%s in the 50-year period, and 5-year survival improved also but at 20% units lower level. Survival gains were found only in patients diagnosed before age 60 years. Survival in vaginal and vulvar cancer followed the same patterns but at a few % units lower level.Cervical cancer screening appeared to have reached its limits in the Nordic countries by year 2000. Novel treatments, such as immunotherapy, would be needed to improve survival until HPV vaccination will reach population coverage and boost the global fight against these cancers.
000179731 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000179731 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179731 650_7 $$2Other$$aAge-specific incidence
000179731 650_7 $$2Other$$aHuman papilloma virus
000179731 650_7 $$2Other$$aIncidence trends
000179731 650_7 $$2Other$$aRelative survival
000179731 650_7 $$2Other$$aRisk factors
000179731 650_2 $$2MeSH$$aDenmark: epidemiology
000179731 650_2 $$2MeSH$$aEarly Detection of Cancer
000179731 650_2 $$2MeSH$$aFemale
000179731 650_2 $$2MeSH$$aFinland: epidemiology
000179731 650_2 $$2MeSH$$aHumans
000179731 650_2 $$2MeSH$$aIncidence
000179731 650_2 $$2MeSH$$aMiddle Aged
000179731 650_2 $$2MeSH$$aNorway: epidemiology
000179731 650_2 $$2MeSH$$aPapillomavirus Infections
000179731 650_2 $$2MeSH$$aSweden: epidemiology
000179731 650_2 $$2MeSH$$aUterine Cervical Neoplasms: prevention & control
000179731 650_2 $$2MeSH$$aUterine Cervical Neoplasms: therapy
000179731 650_2 $$2MeSH$$aVulvar Neoplasms: epidemiology
000179731 650_2 $$2MeSH$$aVulvar Neoplasms: therapy
000179731 7001_ $$aKanerva, Anna$$b1
000179731 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b2$$udkfz
000179731 7001_ $$aHemminki, Akseli$$b3
000179731 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/s12885-022-09582-5$$gVol. 22, no. 1, p. 456$$n1$$p456$$tBMC cancer$$v22$$x1471-2407$$y2022
000179731 909CO $$ooai:inrepo02.dkfz.de:179731$$pVDB
000179731 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000179731 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000179731 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000179731 9141_ $$y2022
000179731 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000179731 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000179731 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000179731 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000179731 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000179731 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-19
000179731 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-19
000179731 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:18:36Z
000179731 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:18:36Z
000179731 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2021-02-14T16:18:36Z
000179731 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-19
000179731 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-19
000179731 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-19
000179731 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-19
000179731 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-19
000179731 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000179731 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000179731 980__ $$ajournal
000179731 980__ $$aVDB
000179731 980__ $$aI:(DE-He78)B062-20160331
000179731 980__ $$aI:(DE-He78)HD01-20160331
000179731 980__ $$aUNRESTRICTED